- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
November 19th 2024, 7:05pm
Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
November 16th 2024, 11:00am
PER® Chemotherapy Foundation Symposium (CFS)
David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
November 15th 2024, 8:42pm
Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC
November 15th 2024, 7:04pm
Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.
Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making
November 14th 2024, 11:30pm
PER® Chemotherapy Foundation Symposium (CFS)
Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.
Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
November 14th 2024, 11:25pm
PER® Chemotherapy Foundation Symposium (CFS)
Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More
November 14th 2024, 9:37pm
PER® Chemotherapy Foundation Symposium (CFS)
Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.
Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma
November 14th 2024, 1:00pm
Transposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.
Piecing Together the Proper BTK Usage in CLL
November 13th 2024, 10:36pm
PER® Chemotherapy Foundation Symposium (CFS)
Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.
Real-World Experience With CAR T Varies From Trials in DLBCL
November 13th 2024, 10:00pm
PER® Chemotherapy Foundation Symposium (CFS)
When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.
BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma
November 13th 2024, 9:39pm
PER® Chemotherapy Foundation Symposium (CFS)
Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.
Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors
November 13th 2024, 3:39pm
Victor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
November 11th 2024, 10:00pm
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.
IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors
November 11th 2024, 9:47pm
The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
Invikafusp Alfa Demonstrates Single-Agent Activity in PD-(L)1–Resistant Solid Tumors
November 11th 2024, 9:33pm
Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.
Temozolomide/Pembrolizumab Plus TTFields Leads to Tumor Control in Newly Diagnosed Glioblastoma
November 11th 2024, 9:14pm
Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.
E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors
November 11th 2024, 9:06pm
E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.
Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma
November 11th 2024, 7:05pm
Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.
THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC
November 8th 2024, 8:20pm
THIO plus cemiplimab displayed durable activity in patients with advanced checkpoint inhibitor–resistant NSCLC.
CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC
November 8th 2024, 8:04pm
Treatment with magrolimab plus docetaxel led to peripheral CD47 saturation in patients with advanced NSCLC, which correlated with improved outcomes.